肝细胞癌17p13.3位点杂合缺失及其临床意义  

Loss of heterozygosity at 17p13.3 and its clinical significance in hepatocellular carcinoma

作　　者：李秋文[1] 肖文华[1] 朱建华[1] 康欢荣[1] 付艳[1] 孙君重[1] 

机构地区：[1]解放军总医院第一附属医院肿瘤科,北京100048

出　　处：《临床肿瘤学杂志》2010年第8期721-724,共4页Chinese Clinical Oncology

摘　　要：目的探讨染色体17p13.3位点杂合缺失与肝细胞癌临床病理参数的关系。方法采用PCR扩增肝细胞癌组织和癌旁正常肝组织17p13.3位点的3个微卫星标志,即D17S643,D17S926和D17S1574,并比较和确定杂合子等位基因缺失。结果 3个微卫星标志总的杂合率为89.8%(79/88),杂合缺失率为41.7%(33/79);杂合缺失与肝细胞癌门静脉癌栓和肝内转移明显相关(P<0.01)。结论染色体17p13.3位点杂合缺失是肝细胞癌最常见的遗传学事件之一,该位点的缺失与肝癌门静脉癌栓和肝内转移密切相关。Objective To explore the correlations between loss of heterozygosity（LOH） at chromosome 17p13.3 and parameters of clinical pathology.Methods Three microsatenite markers of D17S643,D17S926 and D17S1574 at chromosome 17p13.3 were investigated by PCR in 88 pairs of hepatocellular carcinoma tissues and their normal liver tissues.LOH at three microsatenite markers was analyzed.Results There was 89.8% heterozygosity at three microsatenaite in 88 hepatocarcinomas,and 41.7% of them have LOH at least in one of three microsatelite markers.There were significant correlations between LOH and port-vessel cancer-related embolism or intrahepatic metastasis（P〈0.01）.Conclusion LOH at chromosome 17p13.3 is one of the most common genetic events in hepatocellular carcinoma,which is also closely associated with port-vessel cancer-related embolism and intrahepatic metastasis.

关 键 词：肝细胞癌 微卫星标志 杂合缺失 17p13.3 

分 类 号：R735.7[医药卫生—肿瘤]